These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21271584)

  • 1. The use of adalimumab for cricoarytenoid arthritis in ankylosing spondylitis--an effective therapy.
    Desuter G; Duprez T; Huart C; Gardiner Q; Verbruggen G
    Laryngoscope; 2011 Feb; 121(2):335-8. PubMed ID: 21271584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cricoarytenoid arthritis and ankylosing spondylitis.
    Miller FR; Wanamaker JR; Hicks DM; Tucker HM
    Arch Otolaryngol Head Neck Surg; 1994 Feb; 120(2):214-6. PubMed ID: 8297582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cricoarytenoid arthritis in ankylosing spondylitis. A cause of acute respiratory failure and cor pulmonale.
    Libby DM; Schley WS; Smith JP
    Chest; 1981 Nov; 80(5):641-2. PubMed ID: 7297162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
    Kavanaugh A; Tutuncu Z; Catalan-Sanchez T
    Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic approaches for spondyloarthritis.
    Manadan AM; James N; Block JA
    Curr Opin Rheumatol; 2007 May; 19(3):259-64. PubMed ID: 17414952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment.
    Appel H; Janssen L; Listing J; Heydrich R; Rudwaleit M; Sieper J
    Arthritis Res Ther; 2008; 10(5):R125. PubMed ID: 18945353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
    Lozeron P; Denier C; Lacroix C; Adams D
    Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional analysis of cricoarytenoid joint motion.
    Wang RC
    Laryngoscope; 1998 Apr; 108(4 Pt 2 Suppl 86):1-17. PubMed ID: 9546282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor necrosis factor alpha and ankylosing spondylitis.
    Asli B; Wechsler B; Lemaître C
    N Engl J Med; 2003 Jan; 348(4):359-61; author reply 359-61. PubMed ID: 12540654
    [No Abstract]   [Full Text] [Related]  

  • 13. [Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: a case report].
    Azevedo VF; Pietrovski CF; de Almeida Santos M
    Reumatismo; 2010; 62(4):283-5. PubMed ID: 21253622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cricoarytenoid arthritis in a patient with ankylosing spondylitis.
    Bienenstock H; Lanyi VF
    Arch Otolaryngol; 1977 Dec; 103(12):738-9. PubMed ID: 588132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
    da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
    Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers.
    Savastano M; Marioni G; Giacomelli L; Ramonda R; Ferraro SM; Punzi L
    B-ENT; 2010; 6(3):183-8. PubMed ID: 21090160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biological treatment of ankylosing spondylitis].
    Freiesleben S; Schou M
    Ugeskr Laeger; 2008 Jun; 170(24):2140-5. PubMed ID: 18565298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.
    Haibel H; Rudwaleit M; Brandt HC; Grozdanovic Z; Listing J; Kupper H; Braun J; Sieper J
    Arthritis Rheum; 2006 Feb; 54(2):678-81. PubMed ID: 16447247
    [No Abstract]   [Full Text] [Related]  

  • 19. Cricoarytenoid joint arthritis: a possible complication of dermatomyositis.
    Farah C; Tabesh OA; Okais J; Hajjar A; Haddad A
    Pan Afr Med J; 2020; 36():74. PubMed ID: 32774633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.